In what was Devens’ largest land transaction in many years, MassDevelopment recently sold 36.8 acres to an affiliate of King Street Properties, a prominent developer of life science real estate. The company’s solid record of accomplishment presents a rich opportunity for further job growt.
Major local life science landlord King Street Properties paid $4.7 million for a pair of sites at Devens, the former Army base emerging as a Central Massachusetts industrial hub.
Boston-based Samuels & Assoc. is proposing to redevelop a cluster of commercial parcels in the transforming Barry’s Corner section of Allston as a 270-unit apartment complex.
Pursuing lab users continues to be an effective strategy for suburban Boston developers in early 2020, as life science tenants comprised a majority of space commitments in the first quarter.
A pharmaceutical company that recently relocated its headquarters from West Cambridge to Lexington is leasing another 61,000 square feet in a neighboring building.
Commercial landlords trying to capture soaring demand from rapidly growing life science startups are increasingly building out lab space on spec in the hopes of catalyzing the next life science cluster outside of East Cambridge.
A Boston developer is proposing a six-building, 1 million-square-foot multifamily and life science development in one of Cambridge’s last industrial neighborhoods, including an offer to build a pedestrian and bicycle bridge improving access to the MBTA’s Alewife station.
Boston-based developer Samuels & Assoc. is teaming up with Harvard University on a planned multifamily housing and retail project in Allston’s fast-changing Western Avenue corridor.
The success of Boston Landing – which leased brand-new lab space to Roche Diagnostics, incubator SmartLabs and Proteostasis Therapeutics in 2017 – put Allston on the map as a budding life science cluster. Now, life science developers have begun to outbid multifamily competitors for development sites.
Suburban life science developer King Street Properties has been named “Landlord of the Year” by the membership of the Greater Boston Real Estate Board Commercial Brokers Association.
One of Greater Boston’s largest life science developers has made its second acquisition in Framingham with the $20.5 million acquisition of a 153,000-square-foot office and lab complex.
The nation’s largest private developer of life science space is counting on industry growth in Allston, with newly filed plans for a large lab-ready complex on Western Avenue.
Nasdaq-listed biotech company Replimune Group Inc. has leased 63,278 square feet at 33 New York Ave. in Framingham for a new office, lab and pharma manufacturing facility.
Veteran brokers Tom Ragno and Stephen Lynch met for breakfast at Denny’s in Lexington, trying to hash out a stalemate over an office lease negotiation in downtown Boston.
The new owners of commercial properties on Western Avenue in Allston are teaming up with Boston-based developer King Street Properties on plans for a large life science complex and multifamily housing.
Cambridge-based developer King Street Properties’ bet on Framingham’s potential to attract more life science companies has paid off with an anchor lease by a Woburn firm that recently filed for a $100 million initial public offering.
Leases by a pair of local life science companies have driven the occupancy rate at 65 Hayden Ave. in Lexington up to 70 percent.
A California health care REIT has paid $228 million for the 400,000-square-foot Hayden Research Campus in Lexington and is expected to invest in a planned 209,000-square-foot speculative lab building that would expand the Route 128 market’s growing life science cluster.
Cambridge-based King Street Properties has broken ground on a 144,910-square-foot speculative lab and office building.
Cambridge developer King Street Properties has acquired the former Cubist Pharmaceuticals property in Lexington with plans to market 215,000 square feet to small and mid-sized biotech firms.
